Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes
Advanced Science · 2023-08 · 10 (24)
DOI: 10.1002/advs.202300325 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 21.06.2023. Verfasst von Yumin Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 10…. Hauptthemen laut MEDLINE: Ferroptosis, Neurodegenerative Diseases, Stroke. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 403 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science Foundation of AMHT, Science Foundation of ASCH.
Abstract (Originalsprache)
Emerging evidence suggests that ferroptosis, a unique regulated cell death modality that is morphologically and mechanistically different from other forms of cell death, plays a vital role in the pathophysiological process of neurodegenerative diseases, and strokes. Accumulating evidence supports ferroptosis as a critical factor of neurodegenerative diseases and strokes, and pharmacological inhibition of ferroptosis as a therapeutic target for these diseases. In this review article, the core mechanisms of ferroptosis are overviewed and the roles of ferroptosis in neurodegenerative diseases and strokes are described. Finally, the emerging findings in treating neurodegenerative diseases and strokes through pharmacological inhibition of ferroptosis are described. This review demonstrates that pharmacological inhibition of ferroptosis by bioactive small‐molecule compounds (ferroptosis inhibitors) could be effective for treatments of these diseases, and highlights a potential promising therapeutic avenue that could be used to prevent neurodegenerative diseases and strokes. This review article will shed light on developing novel therapeutic regimens by pharmacological inhibition of ferroptosis to slow down the progression of these diseases in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing, 100049, P. R. China.
- Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan, 430000, P. R. China.
- Department of Neurology, The Affiliated Hospital of Chifeng University, Chifeng, 024005, P. R. China.
- Chifeng University Health Science Center, Chifeng, 024000, P. R. China.
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, P.…
ORCID-Profile: Yumin Wang, Hongquan Wang
Förderung
- National Natural Science Foundation of China
- Science Foundation of AMHT
- Science Foundation of ASCH
- Natural Science Foundation of Inner Mongolia Autonomous Region
- Science Foundation of Inner Mongolia Key Laboratory of human genetic diseases
Zitieren
APA
Wang, Y., Wu, S., Li, Q., Sun, H., & Wang, H. (2023). Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes. Advanced Science, 10(24). https://doi.org/10.1002/advs.202300325
Vancouver
Wang Y, Wu S, Li Q, Sun H, Wang H. Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes. Advanced Science. 2023;10(24). doi:10.1002/advs.202300325
BibTeX
@article{Wang2023,
author = {Wang, Yumin and Wu, Shuang and Li, Qiang and Sun, Huiyan and Wang, Hongquan},
title = {Pharmacological Inhibition of Ferroptosis as a Therapeutic Target for Neurodegenerative Diseases and Strokes},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {24},
doi = {10.1002/advs.202300325}
}
EUVIMED